CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 165 filers reported holding CLOVIS ONCOLOGY INC in Q2 2020. The put-call ratio across all filers is 0.78 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,461,000 | -3.9% | 533,832 | 0.0% | 0.02% | 0.0% |
| Q4 2020 | $2,562,000 | -68.3% | 533,832 | -61.5% | 0.02% | -73.7% |
| Q3 2020 | $8,077,000 | -7.8% | 1,385,635 | +6.7% | 0.08% | -18.3% |
| Q2 2020 | $8,765,000 | -14.0% | 1,298,450 | +29.9% | 0.09% | -17.7% |
| Q1 2020 | $10,189,000 | -2.2% | 999,915 | +0.0% | 0.11% | +0.9% |
| Q4 2019 | $10,423,000 | +134.5% | 999,853 | -11.6% | 0.11% | +89.8% |
| Q3 2019 | $4,445,000 | -72.9% | 1,131,123 | +2.1% | 0.06% | -71.2% |
| Q2 2019 | $16,405,000 | -15.4% | 1,108,123 | +41.8% | 0.20% | -17.3% |
| Q1 2019 | $19,401,000 | +268.6% | 781,623 | +166.7% | 0.25% | +206.2% |
| Q4 2018 | $5,264,000 | -17.4% | 293,100 | +35.0% | 0.08% | -4.7% |
| Q3 2018 | $6,376,000 | -28.5% | 217,100 | +10.8% | 0.08% | -39.7% |
| Q2 2018 | $8,913,000 | -3.3% | 196,000 | +12.3% | 0.14% | -10.2% |
| Q1 2018 | $9,214,000 | -22.3% | 174,500 | 0.0% | 0.16% | -23.4% |
| Q4 2017 | $11,866,000 | -33.8% | 174,500 | -19.8% | 0.20% | -34.5% |
| Q3 2017 | $17,922,000 | +13.3% | 217,500 | +28.7% | 0.31% | +5.4% |
| Q2 2017 | $15,824,000 | +107.1% | 169,000 | +40.8% | 0.30% | +100.7% |
| Q1 2017 | $7,641,000 | +31.3% | 120,000 | -8.4% | 0.15% | +10.4% |
| Q4 2016 | $5,819,000 | +8.3% | 131,000 | -12.1% | 0.13% | +3.9% |
| Q3 2016 | $5,371,000 | +732.7% | 149,000 | +217.0% | 0.13% | +658.8% |
| Q2 2016 | $645,000 | +5.6% | 47,000 | +46.9% | 0.02% | +13.3% |
| Q1 2016 | $611,000 | -51.9% | 32,000 | -11.8% | 0.02% | -55.9% |
| Q4 2015 | $1,271,000 | -67.7% | 36,300 | -15.2% | 0.03% | -64.9% |
| Q3 2015 | $3,936,000 | -25.4% | 42,800 | -28.7% | 0.10% | -11.8% |
| Q2 2015 | $5,273,000 | +1.5% | 60,000 | -14.3% | 0.11% | +4.8% |
| Q1 2015 | $5,197,000 | -14.9% | 70,000 | -35.8% | 0.10% | -18.0% |
| Q4 2014 | $6,104,000 | – | 109,000 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $60,485,054,000 | 53.20% |
| Palo Alto Investors LP | 2,121,857 | $157,505,000 | 7.79% |
| NEA Management Company, LLC | 2,279,781 | $169,228,000 | 7.65% |
| EcoR1 Capital, LLC | 243,048 | $18,041,000 | 6.01% |
| Redmile Group, LLC | 900,879 | $66,872,000 | 6.00% |
| Opaleye Management Inc. | 140,000 | $10,392,000 | 4.82% |
| PFM Health Sciences, LP | 2,266,756 | $168,261,000 | 4.64% |
| Partner Investment Management, L.P. | 40,798 | $3,028,000 | 4.56% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 826,919 | $61,383,000 | 3.74% |
| Opus Point Partners Management, LLC | 55,988 | $4,156,000 | 3.48% |